These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 35780062)

  • 21. Chimeric antigen receptor T cells for acute lymphoblastic leukemia.
    Frey NV
    Am J Hematol; 2019 May; 94(S1):S24-S27. PubMed ID: 30784101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent Advances in CAR-T Therapy.
    Ali MB
    Cancer Control; 2024; 31():10732748241263713. PubMed ID: 38910268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New targets for CAR T therapy in hematologic malignancies.
    Savani M; Oluwole O; Dholaria B
    Best Pract Res Clin Haematol; 2021 Sep; 34(3):101277. PubMed ID: 34625226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric Antigen Receptor T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: Current Landscape in 2021.
    Gauthier J; Turtle CJ
    Cancer J; 2021 Mar-Apr 01; 27(2):98-106. PubMed ID: 33750068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric antigen receptor T-cell therapy: Foundational science and clinical knowledge for pharmacy practice.
    Dushenkov A; Jungsuwadee P
    J Oncol Pharm Pract; 2019 Jul; 25(5):1217-1225. PubMed ID: 30890066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic Mechanism of Leukemia Relapse Following CD19 Chimeric Antigen Receptor T Cell Therapy.
    Qiu S; Pan Y; Shi S; Omotoyosi FF; Chen K; Guo Z; Lü P
    Cancer Biother Radiopharm; 2022 Jun; 37(5):335-341. PubMed ID: 33739864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
    Brudno JN; Kochenderfer JN
    Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
    Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
    Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
    Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
    Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma.
    Xu H; Lv Q; Huang L; Cao W; Wang J; Meng F; Li C; Zheng M; Chen L; Mu K; Cheng J; Zhu L; Zhou J; Zhang Y; Wang N; Cao Y
    Cytotherapy; 2023 Feb; 25(2):185-191. PubMed ID: 36283943
    [No Abstract]   [Full Text] [Related]  

  • 31. [Gene-modified T-cell therapy using chimeric antigen receptors for pediatric hematologic malignancies].
    Nakazawa Y
    Rinsho Ketsueki; 2016 Jun; 57(6):701-8. PubMed ID: 27384848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress.
    Holstein SA; Lunning MA
    Clin Pharmacol Ther; 2020 Jan; 107(1):112-122. PubMed ID: 31622496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
    Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
    J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.
    Sun W; Liang AB; Huang H; Huang XJ
    Haematologica; 2023 Aug; 108(8):2011-2028. PubMed ID: 36794504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of chimeric antigen T-cell therapy in chronic lymphocytic leukemia.
    Siddiqi T
    Clin Adv Hematol Oncol; 2022 Jun; 20(6):366-368. PubMed ID: 35731607
    [No Abstract]   [Full Text] [Related]  

  • 36. Chimeric Antigen Receptor T Cell Therapy in Patients with Multiply Relapsed or Refractory Extramedullary Leukemia.
    Rubinstein JD; Krupski C; Nelson AS; O'Brien MM; Davies SM; Phillips CL
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):e280-e285. PubMed ID: 32755637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.
    Hill JA; Seo SK
    Blood; 2020 Aug; 136(8):925-935. PubMed ID: 32582924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis.
    Mohyuddin GR; Atieh T; Ahmed N; Sborov D; McClune B; Abdallah AO; Goodman AM; Aziz M; Allen I; Prasad V
    Eur J Cancer; 2021 Oct; 156():164-174. PubMed ID: 34454318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Critical care management of chimeric antigen receptor T-cell therapy recipients.
    Shimabukuro-Vornhagen A; Böll B; Schellongowski P; Valade S; Metaxa V; Azoulay E; von Bergwelt-Baildon M
    CA Cancer J Clin; 2022 Jan; 72(1):78-93. PubMed ID: 34613616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.